

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

PHARMACIA CORP /DE/
Form 10-Q
August 14, 2001

1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From to

Commission File Number 1-2516

PHARMACIA CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

43-0420020
(I. R. S. Employer
Identification No.)

Pharmacia Corporation, 100 Route 206 North, Peapack, NJ 07977
(Address of principal executive offices) (Zip Code)

Registrant's telephone number 908/901-8000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months, and (2) has been subject to such filing requirements for the past 90 days. YES X NO

The number of shares of Common Stock, \$2 Par Value, outstanding as of August 9, 2001 was 1,301,517,238

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

2

QUARTERLY REPORT ON FORM 10-Q

PHARMACIA CORPORATION

QUARTER ENDED JUNE 30, 2001

INDEX OF INFORMATION INCLUDED IN REPORT

	Page
PART I - FINANCIAL INFORMATION	3
Item 1. Financial Statements	3
Consolidated Statements of Earnings	3
Condensed Consolidated Statements of Cash Flows	4
Condensed Consolidated Balance Sheets	5
Notes to Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures about Market Risk	29
PART II - OTHER INFORMATION	30
Item 5. Other Information	30
Item 6. Exhibits and Reports on Form 8-K	30

2

3

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PHARMACIA CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(Dollars in millions, except per-share data)
(Unaudited)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2001	2000	2001	2000
	-----	-----	-----	-----
Net sales	\$ 5,424	\$ 5,187	\$ 9,940	\$ 9,359
Cost of products sold	1,559	1,513	3,000	2,917
Research and development	664	716	1,411	1,411
Selling, general and administrative	1,780	1,754	3,503	3,356
Amortization and adjustment of goodwill	55	145	116	202
Merger and restructuring	206	111	351	572
Interest expense	88	104	170	201

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Interest income	(30)	(25)	(69)	(54)
All other, net	(4)	28	13	(31)

Earnings before income taxes and minority interest	1,106	841	1,445	785
Provision for income taxes	296	303	373	278
Minority interest in agricultural subsidiaries, net of tax	58	--	66	--

Earnings from continuing operations	752	538	1,006	507
Loss on sale of discontinued operations, net of tax	(3)	(59)	(8)	(1)

Earnings before extraordinary items and cumulative effect of accounting change	749	479	998	506
Extraordinary items, net of tax	(12)	--	(12)	--
Cumulative effect of accounting change, net of tax	--	--	1	(198)

Net earnings	\$ 737	\$ 479	\$ 987	\$ 308
=====				
Net earnings per common share:				
Basic				
Earnings from continuing operations	\$.58	\$.42	\$.77	\$.39
Net earnings	.57	.38	.76	.24
Diluted				
Earnings from continuing operations	\$.56	\$.41	\$.75	\$.39
Net earnings	.55	.37	.74	.24
=====				

See accompanying notes.

3

4

PHARMACIA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in millions)
(Unaudited)

	For the Six Months Ended June	
	2001	2000
	-----	-----
Net cash provided (required) by continuing operations	\$ 86	\$ (450)
Net cash (required) by discontinued operations	--	(1)

Net cash provided (required) by operations	86	(451)

Cash flows (required) provided by investment activities:		
Proceeds from sale of subsidiaries	--	75
Purchases of subsidiaries	(65)	(4)
Proceeds from sales of investments	78	91

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Purchases of other acquisitions and investments	(81)	(226)
Purchases of property, plant and equipment	(553)	(643)
Proceeds from sale of discontinued operations, net	--	1,077
Other	(29)	5

Net cash (required) provided by investment activities	(650)	375

Cash flows provided (required) by financing activities:		
Proceeds from issuance of debt	--	12
Repayment of debt	(65)	(379)
Payments of ESOP debt	(85)	(31)
Net increase (decrease) in short-term borrowings	779	(33)
Dividend payments	(319)	(334)
Issuance of stock	158	480

Net cash provided (required) by financing activities	468	(285)

Effect of exchange rate changes on cash	(70)	(40)

Net change in cash and cash equivalents	(166)	(401)
Cash and cash equivalents, beginning of year	2,166	1,600

Cash and cash equivalents, end of period	\$ 2,000	\$ 1,199
=====		

See accompanying notes.

4

5

PHARMACIA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in millions)
(Unaudited)

	June 30, 2001	December 31, 2000
	-----	-----
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 2,000	\$ 2,166
Trade accounts receivable, less allowance of \$292 (2000: \$292)	5,966	5,025
Inventories	2,721	2,772
Other current assets	1,858	1,604

Total current assets	12,545	11,567
Long-term investments	297	444
Properties, net	7,155	7,171
Goodwill and other intangible assets, net	5,009	5,259
Other noncurrent assets	1,834	2,215

Total assets	\$ 26,840	\$ 26,656
=====		

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Short-term debt, including current maturities of long-term debt	\$ 2,312	\$ 833
Accounts payable	1,249	1,361
Other current liabilities	3,572	3,967

Total current liabilities	7,133	6,161
Long-term debt and guarantee of ESOP debt	3,718	4,586
Other noncurrent liabilities	2,562	2,904
Minority interest in agricultural subsidiaries	1,105	1,084

Total liabilities	14,518	14,735

Shareholders' equity:		
Preferred stock, one cent par value; at stated value; authorized 10 million shares; issued 6,462 shares (2000: 6,518 shares)	160	263
Common stock, two dollar par value; authorized 3 billion shares; issued 1.468 billion shares	2,937	2,937
Capital in excess of par value	2,762	2,694
Retained earnings	11,418	10,781
ESOP-related accounts	(296)	(307)
Treasury stock	(1,955)	(2,003)
Accumulated other comprehensive loss	(2,704)	(2,444)

Total shareholders' equity	12,322	11,921

Total liabilities and shareholders' equity	\$ 26,840	\$ 26,656
=====		

See accompanying notes.

5

6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED
(DOLLARS IN MILLIONS, EXCEPT PER-SHARE DATA
UNLESS OTHERWISE INDICATED)

Trademarks are indicated in all upper case letters. In the notes that follow, per-share amounts are presented on a diluted, after-tax basis.

The term "the company" is used to refer to Pharmacia Corporation or to Pharmacia Corporation and its subsidiaries, as appropriate to the context. The term "former Monsanto" is used to refer to pre-merger operations of the former Monsanto Company and "Monsanto" refers to the agricultural subsidiary.

A - INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial information presented herein is unaudited, other than the condensed balance sheet at December 31, 2000, which is derived from audited financial statements. The interim financial statements and notes thereto do not include all disclosures required by generally accepted accounting principles and should be read in conjunction with the financial statements and notes thereto included in Pharmacia Corporation's annual report filed on Form 10-K for the year ended December 31, 2000.

In the opinion of management, the interim financial statements reflect all adjustments of a normal recurring nature necessary for a fair statement of the results for interim periods. The current period's results of operations are not necessarily indicative of results that ultimately may be achieved for the year.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

B - NEW ACCOUNTING STANDARDS

DERIVATIVE INSTRUMENTS AND HEDGING

On January 1, 2001, the company adopted Statement of Financial Accounting Standards No.133, "Accounting for Derivative Instruments and Hedging Activities" (SFAS 133) and its amendments. This statement requires companies to record derivatives on the balance sheet as assets and liabilities measured at fair value. The accounting treatment of gains and losses resulting from changes in the value of derivatives depends on the use of the derivative and whether it qualifies for hedge accounting. Gains and losses on non-hedging instruments attributable to changes in the fair value are recorded in earnings. If elected and qualified, special hedge accounting is available whereby gains and losses on derivatives and certain other instruments can be offset or deferred.

In accordance with the transition provisions of SFAS 133, the company recorded a net-of-tax cumulative effect adjustment in earnings as of January 1, 2001 for approximately a \$1 gain. This amount is comprised of the excluded component of instruments previously designated in cash flow hedges and other changes in recorded basis to bring derivatives to fair value, both of which were less than \$1 on an individual basis. Also included in the \$1 gain were offsetting adjustments to the carrying value of a hedged item and the hedging derivative for a fair value hedge each in the amount of \$19. A similar cumulative effect adjustment in the amount of \$3 (net of tax) has been made on the balance sheet to other comprehensive income. This amount reflects the deferred amount of derivative instruments previously designated in cash flow hedges.

6

7

Upon adopting SFAS 133, the company elected to reclassify \$52 of held-to-maturity securities as available-for-sale securities. The unrealized gain associated with the reclassification was not material and is recorded in other comprehensive income. Under the provisions of SFAS 133, such a reclassification does not call into question the company's intent to hold current or future debt securities until their maturity.

REVENUE RECOGNITION

In connection with the fourth quarter 2000 adoption of the interpretations of Securities and Exchange Commission (SEC) Staff Accounting Bulletin 101, "Revenue Recognition in Financial Statements" (SAB 101), the company recorded a cumulative effect of a change in accounting principle, effective January 1, 2000, and has restated the quarterly results of 2000 as if SAB 101 had been applied for each quarter. For a further discussion of this accounting change, see the company's Form 10-K for the year ended December 31, 2000.

C - ACQUISITION

During March 2001, the company completed the acquisition of Sensus Drug Development Corporation by purchasing the remaining 80.1 percent of its stock. The assets purchased were valued at \$117, which includes \$67 allocated to in-process research and development. Cash paid in connection with this purchase was \$65 and included certain direct closing costs and is net of contractual holdback amounts.

D - EXTRAORDINARY ITEMS

On June 28, 2001, the company retired certain debt obligations relating to one of the employee stock ownership plans. The principal amount of the debt was \$65.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Certain costs related to the transaction, including a premium to retire the debt and other direct costs, were \$4 (net of taxes of \$2) and have been classified as an extraordinary item on the company's consolidated statements of earnings.

Through a private transaction entered into on June 29, 2001, the company retired debt related to the adjustable conversion-rate equity securities (ACES) in the principal amount of \$700. Premium on the debt and other direct costs of \$8 (net of taxes of \$5) were accrued as an extraordinary item.

E - COMPREHENSIVE INCOME

Comprehensive income for the three months ended June 30, 2001 and 2000 was \$708 and \$319, respectively. Comprehensive income for the six months ended June 30, 2001 and 2000 was \$727 and \$423, respectively.

F - MERGER AND RESTRUCTURING CHARGES

The company recorded an additional \$216 of merger and restructuring charges during the second quarter of 2001 in connection with the merger and integration of the former Monsanto and Pharmacia & Upjohn companies into Pharmacia Corporation. These charges are part of the comprehensive integration plan approved by the board of directors during 2000. Of the total charges in the quarter, \$206, comprised of \$138 of merger costs and \$68 of restructuring expenses, was recorded on the merger and restructuring line of the consolidated statements of earnings and an additional \$10 was recorded in cost of products sold.

7

8

For the six months ended June 30, 2001, the company recorded a total of \$362 of merger and restructuring costs. Of this total, \$351, comprised of \$194 of merger costs and \$157 of restructuring expenses, was recorded on the merger and restructuring line of the consolidated statements of earnings and an additional \$11 was recorded in cost of products sold.

The \$194 of 2001 merger costs includes costs incurred to integrate the former companies into a single organization such as consultant and relocation costs. This effort includes the company's plan to exit its Sweden-based metabolic diseases research activities, biopharmaceutical development unit and the company's plasma business. As a result of this effort, the company entered into a definitive agreement on June 7, 2001, related to the partial divestiture of these operations, establishing Biovitrum AB (Biovitrum). The related estimated loss of \$50 is included within the second quarter 2001 merger costs and included the write-down of the net assets to market value and certain transaction-related expenses. Under the Biovitrum-related agreements, Pharmacia will initially retain ownership of approximately 35 percent of the new company with the remaining shares owned by outside investors. It is possible that Pharmacia's share will be further reduced to below 20 percent as additional outside investors may participate in the new company by acquiring shares from Pharmacia. At the current 35 percent ownership level, the company will account for its share of Biovitrum using the equity method of accounting following the closing of the transaction. The closing occurred on July 31, 2001 and, accordingly, there were no cash flows associated with the transaction in the second quarter.

The \$78 of aggregate restructuring costs for the quarter comprises \$28 related to prescription pharmaceuticals, \$9 associated with corporate and administrative functions and \$41 in connection with the agricultural subsidiary. On a year-to-date basis, the company has recorded \$168 of aggregate restructuring charges as follows: \$88 associated with prescription pharmaceuticals, \$15 associated with corporate and administrative functions, \$2 in connection with other pharmaceutical operations and \$63 related to the agricultural subsidiary.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

The \$28 relating to prescription pharmaceuticals consists of \$17 in connection with the involuntary termination of approximately 70 employees and \$11 relating to asset impairments. For the six months ended June 30, 2001, the \$88 total restructuring charges associated with prescription pharmaceuticals comprises \$63 in connection with the separation of approximately 360 employees, \$17 resulting from asset impairments and \$8 associated with other exit costs.

The \$9 associated with the corporate and administrative functions for the quarter includes \$4 relating to the involuntary separation of approximately 30 employees and \$5 resulting from asset impairments. The 2001 year-to-date total of \$15 for corporate and administrative functions includes \$10 relating to the separation of approximately 90 employees and the \$5 of asset impairments. Although there are no charges associated with the other pharmaceutical operations during the second quarter 2001, the year-to-date restructuring balance includes \$2 associated with the separation of approximately 10 employees.

The \$41 of agricultural subsidiary restructuring charges for the quarter is composed of \$31 on the merger and restructuring line and \$10 on the cost of products sold line related to the write-off of inventories in connection with Monsanto's restructuring plan. The \$31 in merger and restructuring comprises \$5 relating to workforce reduction costs associated with the involuntary separation of approximately 110 employees, \$14 relating to facility closures and other exit costs including contract terminations resulting from the exit of certain research programs and non-core activities, and \$12 relating to the write-off of assets. For the 2001 year-to-date total of \$63 (\$11 in cost of products sold and \$52 in merger and restructuring), Monsanto recorded \$20 in connection with the involuntary separation of approximately 230 employees, \$18 relating to facility closures and other exit costs, \$14 in connection with the write-down of assets and \$11 in cost of products sold in connection with the write-off of inventories.

8

9

During the second quarter of 2000, the company recorded aggregate merger and restructuring charges of \$227. During that quarter, the company recorded on the merger and restructuring line an additional \$7 of merger costs, totaling approximately \$470 in merger-related costs for the first six months of 2000. These merger-related costs are comprised, in part, of transaction costs including investment bankers, attorneys, registration and regulatory fees and other professional services. In addition, these costs included various employee incentive and change-of-control costs directly associated with the merger. The latter includes a non-cash charge of \$232 during the first quarter that was related to certain employee stock options that were repriced in conjunction with the merger pursuant to change of control provisions. Pursuant to the terms of these "premium options," at consummation of the merger, the original above-market exercise price was reduced to equal the fair market value on the date of grant.

The \$220 of additional charges during the second quarter of 2000 represents restructuring charges and was recorded on several lines of the consolidated statements of earnings. \$104 was recorded on the merger and restructuring line and included \$90 associated with the involuntary separation of 424 employees and \$14 relating to asset impairments and contract termination costs. An inventory write-off of \$32 was recorded in cost of products sold and goodwill impairments of \$84 were recorded in the amortization and adjustment of goodwill line, both in connection with the restructuring of the agricultural subsidiary.

Of the second-quarter 2000 charges to merger and restructuring, \$59 relates to the restructuring of corporate functions including the involuntary separation of 49 employees, primarily the result of duplicate positions. The remaining \$45 of

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

charges are associated with the restructuring of agricultural products operations and include the involuntary separation of 375 employees throughout the world, mainly in research and development.

A rollforward from year-end 2000 of restructuring charges and spending associated with the current restructuring plans relating to the integration of the former Monsanto and Pharmacia & Upjohn companies and the restructuring of the agricultural products and other pharmaceutical operations is included in the table below. As of June 30, 2001, the company has paid a total of \$369 relating to the separation of approximately 2,745 employees associated with these restructuring plans.

	Workforce Reductions	Other Exit Costs	Total
December 31, 2000	\$ 192	\$ 15	\$ 207
Year-to-date charges	95	26	121
Year-to-date spending	(222)	(24)	(246)
June 30, 2001	\$ 65	\$ 17	\$ 82

G - EARNINGS PER SHARE

Basic earnings per share is computed by dividing the earnings measure by the weighted average number of shares of common stock outstanding. Diluted earnings per share is computed assuming the exercise of stock options, conversion of preferred stock, and the issuance of stock as incentive compensation to certain employees. Also in the diluted computation, earnings from continuing operations and net earnings are reduced by an incremental contribution to the Employee Stock Ownership Plan (ESOP). This contribution is the after-tax difference between the income that the ESOP would have received in preferred stock dividends and the dividend on the common shares assumed to have been outstanding.

9

10

The following table reconciles the numerators and denominators of the basic and diluted earnings per share computations:

	For the Three Months Ended June 30,			
	2001 Basic	2001 Diluted	2000 Basic	2000 Diluted
EPS numerator:				
Earnings from continuing operations	\$ 752	\$ 752	\$ 538	\$ 538
Less: Preferred stock dividends, net of tax	(3)	--	(3)	--
Less: ESOP contribution, net of tax	--	(2)	--	(2)
Earnings from continuing operations available to common shareholders	\$ 749	\$ 750	\$ 535	\$ 536
EPS denominator:				

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Average common shares outstanding	1,300	1,300	1,269	1,269
Effect of dilutive securities:				
Stock options and stock warrants	--	13	--	26
Convertible instruments and incentive compensation	--	13	--	13

Total shares (in millions)	1,300	1,326	1,269	1,308
=====				
Earnings (loss) per share:				
Continuing operations	\$.58	\$.56	\$.42	\$.41
Discontinued operations	--	--	(.04)	(.04)
Extraordinary items	(.01)	(.01)	--	--

Net earnings	\$.57	\$.55	\$.38	\$.37
=====				

	For the Six Months Ended June 30,			
	2001 Basic	2001 Diluted	2000 Basic	2000 Diluted
	-----	-----	-----	-----
EPS numerator:				
Earnings from continuing operations	\$ 1,006	\$ 1,006	\$ 507	\$ 507
Less: Preferred stock dividends, net of tax	(6)	--	(6)	--
Less: ESOP contribution, net of tax	--	(4)	--	(4)

Earnings from continuing operations available to common shareholders	\$1,000	\$ 1,002	\$ 501	\$ 503
=====				
EPS denominator:				
Average common shares outstanding	1,299	1,299	1,263	1,263
Effect of dilutive securities:				
Stock options and stock warrants	--	16	--	19
Convertible instruments and incentive compensation	--	12	--	12

Total shares (in millions)	1,299	1,327	1,263	1,294
=====				
Earnings (loss) per share:				
Continuing operations	\$.77	\$.75	\$.39	\$.39
Discontinued operations	--	--	--	--
Extraordinary items	(.01)	(.01)	--	--
Cumulative effect of accounting change	--	--	(.15)	(.15)

Net earnings	\$.76	\$.74	\$.24	\$.24
=====				

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Estimated replacement cost (FIFO basis):		
Finished products	\$ 793	\$ 1,042
Raw materials, supplies and work-in-process	2,145	1,941

Inventories (FIFO basis)	2,938	2,983
Less reduction to LIFO cost	(217)	(211)

Inventories	\$ 2,721	\$ 2,772
=====		

Inventories valued on the LIFO method had an estimated replacement cost (FIFO basis) of \$1,301 at June 30, 2001, and \$1,434 at December 31, 2000.

I - COMMITMENTS, CONTINGENT LIABILITIES AND LITIGATION

The consolidated balance sheets include accruals for estimated product, intellectual property and other litigation and environmental liabilities. The latter includes exposures related to discontinued operations, including the industrial chemical facility referred to below and several sites which, under the Comprehensive Environmental Response, Compensation, and Liability Act, are commonly known as Superfund sites. The company's ultimate liability in connection with Superfund sites depends on many factors, including the number of other responsible parties and their financial viability and the remediation methods and technology to be used. Actual costs to be incurred may vary from the estimates, given the inherent uncertainties in evaluating environmental exposures.

ENVIRONMENTAL MATTERS

With regard to the company's discontinued industrial chemical facility in North Haven, Connecticut, the company will be required to submit a corrective measures study report to the U.S. Environmental Protection Agency (EPA). It is reasonably possible that a material increase in accrued liabilities will be required. It is not possible, however, to estimate a range of potential losses. Accordingly, it is not possible to determine what, if any, additional exposure exists at this time.

LITIGATION MATTERS

On March 20, 1998, a jury verdict was returned against Pharmacia in a lawsuit filed in the California Superior Court. The lawsuit was brought by Mycogen Corporation (Mycogen), Agrigenetics, Inc. and Mycogen Plant Science, Inc. claiming that Pharmacia delayed providing access to certain gene technology under a 1989 agreement with Lubrizol Genetics Inc., a company which Mycogen subsequently purchased. The jury awarded \$174.9 in future damages. This jury award was overturned on appeal by the California Court of Appeals. The California Supreme Court has granted Mycogen's petition requesting further review. Monsanto will continue to vigorously pursue its position on appeal. No provision has been made in the company's consolidated financial statements with respect to this verdict.

In April 1999, a jury verdict was returned against DEKALB Genetics (DEKALB) (which is now a wholly owned subsidiary of Monsanto) in a lawsuit filed in U.S. District Court in North Carolina. The lawsuit was brought by Aventis CropScience S.A. (formerly Rhone Poulenc Agrochimie S.A.) (Aventis), claiming that a 1994 license agreement was induced by fraud stemming from DEKALB's nondisclosure of

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

relevant information and that DEKALB did not have the right to license, make or sell products using Aventis's technology for glyphosate resistance under this agreement. The jury awarded Aventis \$15 in actual damages for unjust enrichment and \$50 in punitive damages. DEKALB has appealed this verdict, believes it has meritorious grounds to overturn the verdict and intends to vigorously pursue all available means to have the verdict overturned. An arbitration has been filed on behalf of Calgene LLC, a wholly-owned subsidiary of Monsanto, claiming that as a former partner of Aventis, Calgene is entitled to at least half of any damages, royalties or other amounts recovered by Aventis from Monsanto or DEKALB pursuant to these proceedings. No provision has been made in the company's consolidated financial statements with respect to the award for punitive damages.

The company has been a party along with a number of other defendants (both manufacturers and wholesalers) in several federal civil antitrust lawsuits, some of which were consolidated and transferred to the Federal District Court for the Northern District of Illinois. These suits, brought by independent pharmacies and chains, generally allege unlawful conspiracy, price discrimination and price fixing and, in some cases, unfair competition. These suits specifically allege that the company and the other named defendants violated the following: (1) the Robinson-Patman Act by giving substantial discounts to hospitals, nursing homes, mail-order pharmacies and health maintenance organizations without offering the same discounts to retail drugstores, and (2) Section 1 of the Sherman Antitrust Act by entering into agreements with other manufacturers and wholesalers to restrict certain discounts and rebates so they benefited only favored customers.

The Federal District Court for the Northern District of Illinois certified a national class of retail pharmacies in November 1994. Pharmacia & Upjohn Company, a subsidiary of the company, announced in 1998 that it reached a settlement with the plaintiffs in the federal class action cases for \$103; and Searle, also a subsidiary of the company, received a favorable verdict in 1999. Eighteen class action lawsuits seeking damages based on the same alleged conduct were filed in 14 states and the District of Columbia. The plaintiffs claim to represent consumers who purchased prescription drugs in those jurisdictions and four other states. All but one of the state cases have been dismissed or settled. All that remain of the federal cases are those brought by plaintiffs who opted out of the federal class and have Robinson-Patman Act and Sherman Antitrust Act claims.

On April 11, 2000, the University of Rochester filed suit in U.S. District Court for the Western District of New York, asserting patent infringement against the company and certain of its subsidiaries as well as Pfizer, Inc. The University asserts that its U.S. patent granted on April 11, 2000, is infringed by the sale and use of CELEBREX. The patent has claims directed to a method of treating human patients by administering a selective COX-2 inhibitor. The University has sought injunctive relief, as well as monetary compensation for infringement of the patent. The trial date is tentatively scheduled for September 2002.

The company is also a defendant in a suit filed by Great Lakes Chemical Company. The original complaint was filed in the U.S. District Court in Delaware on January 20, 2000, alleging violations of Federal and Indiana Securities Laws, common law fraud and breach of contract claims. The lawsuit itself is a result of Great Lakes' purchase of the NSC Technologies unit of former Monsanto. According to Great Lakes, NSC's actual sales for 1999 were significantly below the projected sales. On May 25, 2000, the Federal Court dismissed Great Lakes' complaint for lack of federal subject matter jurisdiction holding that the sale of NSC was not a "security" under federal law. On June 9, 2000, Great Lakes filed a new complaint in Delaware Superior Court. The company's motion to move the case from Superior Court to Delaware Equity Court was granted. On February 13, 2001, oral argument was held on the company's motion to dismiss the state court action. In a ruling issued June 29, 2001, the Court dismissed Counts I, II, III and VII of the

13

Great Lakes Complaint, disposing of the fraud allegations and precluding the possibility of punitive damages, thereby significantly reducing the company's exposure, to the extent there was any exposure. Discovery is now proceeding on the remaining counts.

On April 12, 2001, the company was sued by CP Kelco in the U.S. District Court in Delaware. CP Kelco is seeking compensatory and punitive damages for alleged breach of contract, common law fraud and securities law violations arising from the sale of the business. Lehman Brothers Merchant Banking Partners II, L.P. purchased the Kelco biogums business from the company for \$592 to form CP Kelco with a combination of the Kelco biogums business and a business purchased from Hercules, Inc. According to CP Kelco, their financial projections for the Kelco biogums business were materially lower than the projections provided by company management before the closing of the transaction, which occurred on September 28, 2000. The original asset purchase agreement was executed between the company and CP Kelco on February 22, 2000 and amended twice: on August 7, 2000 and September 15, 2000. The company believes the allegations of CP Kelco to be without merit and intends to defend them vigorously. The company has asserted counterclaims against CP Kelco for the return of certain payments and specific performance of its obligation under the Asset Purchase Agreement to provide certain severance benefits to certain transferred employees. The company also has asserted indemnification and other, related claims against Lehman Brothers Merchant Banking Partners II, L.P. Hercules, Inc. and Hercules 2000, LLC in a third party complaint. Discovery has begun in the lawsuit.

With respect to the matters described above for which no range has been given, the company believes it is not possible to estimate a range of potential losses at this time. Accordingly, it is not possible to determine what, if any, additional exposure exists at this time. The company intends to vigorously defend itself in these matters.

The company is involved in other legal proceedings arising in the ordinary course of its business. While the results of litigation cannot be predicted with certainty, management's belief is that any potential remaining liability from such proceedings that might exceed amounts already accrued will not have a material adverse effect on the company's consolidated financial position, profitability or liquidity.

J - SEGMENT INFORMATION

The company's reportable segments are organized principally by product line. They are: Prescription Pharmaceuticals, Agricultural Productivity, and Seeds and Genomics. The Prescription Pharmaceuticals segment includes general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. The Agricultural Productivity segment consists of crop protection products, animal agriculture and environmental technologies business lines. The Seeds and Genomics segment is comprised of global seeds and related trait businesses and genetic technology platforms.

The company also operates several business units that do not constitute reportable business segments. These operating units include consumer health care, animal health, diagnostics, plasma, pharmaceutical commercial services and biotechnology. Due to the size of these operating units, they have been included in an "Other Pharmaceuticals" category.

Corporate amounts represent general and administrative expenses of Pharmacia corporate support functions, restructuring charges relating to the pharmaceutical and corporate functions and other corporate items such as litigation accruals, merger costs and non-operating income and expense.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Corporate support functions and costs are allocated to agricultural segments. Accordingly, these costs are only shown separately in the following table for the non-agricultural segments. Certain goodwill and intangible assets and associated amortization are not allocated to segments.

The following tables show revenues and earnings for the company's operating segments and reconciling items necessary to total to the amounts reported in the consolidated financial statements. Information about interest income and expense, and income taxes is not provided on a segment level as the segments are reviewed based on earnings before interest and income taxes (EBIT). There are no inter-segment revenues. Long-lived assets are not allocated to

13

14

segments and, accordingly, depreciation is not available on a segment basis. Historical segment information has been restated to conform to the current presentation.

	For the Three Months Ended June 30,			
	Net Sales		EBIT*	
	2001	2000	2001	2000
	-----	-----	-----	-----
Prescription Pharmaceuticals	\$ 2,943	\$ 2,732	\$ 719	\$ 476
Other Pharmaceuticals	470	448	100	95
Corporate	--	--	(305)	(162)
<hr/>				
Total Pharmaceuticals & Corporate	3,413	3,180	514	409
<hr/>				
Agricultural Productivity	1,574	1,461	635	605
Seeds & Genomics	437	546	15	(94)
<hr/>				
Total Agricultural	2,011	2,007	650	511
<hr/>				
Total Pharmacia	\$ 5,424	\$ 5,187	1,164	920
<hr/>				
Interest expense, net			(58)	(79)
Income tax provision			(296)	(303)
Minority interest in agricultural subsidiaries, net of tax			(58)	--
<hr/>				
Net earnings from continuing operations			\$ 752	\$ 538
<hr/>				

	For the Six Months Ended June 30,			
	Net Sales		EBIT*	
	2001	2000	2001	2000
	-----	-----	-----	-----
Prescription Pharmaceuticals	\$ 5,672	\$ 5,106	\$ 1,156	\$ 906
Other Pharmaceuticals	951	925	204	198
Corporate	--	--	(571)	(814)
<hr/>				
Total Pharmaceuticals & Corporate	6,623	6,031	789	290
<hr/>				

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Agricultural Productivity	2,382	2,294	774	803
Seeds & Genomics	935	1,034	(17)	(161)

Total Agricultural	3,317	3,328	757	642

Total Pharmacia	\$ 9,940	\$ 9,359	1,546	932
=====				
Interest expense, net			(101)	(147)
Income tax provision			(373)	(278)
Minority interest in agricultural subsidiaries, net of tax			(66)	--

Net earnings from continuing operations			\$ 1,006	\$ 507
=====				

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flows or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company.

14

15

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Trademarks of Pharmacia Corporation and its subsidiaries are indicated in all upper case letters. In the following discussion of consolidated results, per-share amounts are presented on a diluted, after-tax basis.

The term "the company" is used to refer to Pharmacia Corporation or to Pharmacia Corporation and its subsidiaries, as appropriate to the context. The term "former Monsanto" is used to refer to pre-merger operations of the former Monsanto Company and "Monsanto" refers to the agricultural subsidiary.

FINANCIAL REVIEW

OVERVIEW

The table below provides a comparative overview of consolidated results for the second quarter and first six-month periods of 2001 and 2000 in millions of dollars, except per-share data.

	For the Three Months Ended June 30,			For t
	2001	Percent Change	2000	2001
	----	-----	----	----
Net sales	\$ 5,424	5%	\$ 5,187	\$ 9,940
Earnings from continuing operations before interest and income taxes*	1,164	27	920	1,546

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Earnings from continuing operations	752	40	538	1,006
Discontinued operations	(3)	n.m.	(59)	(8)
Extraordinary Items	(12)	n.m.	--	(12)
Cumulative effect of accounting change	--	n.m.	--	1
Net earnings	737	54	479	987
Net earnings per common share:				
Continuing operations:				
Basic	\$.58	38%	\$.42	\$.77
Diluted	.56	37	.41	.75
Net earnings				
Basic	\$.57	50	\$.38	\$.76
Diluted	.55	49	.37	.74

n.m. = not meaningful

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company.

15

16

Quarter-to-quarter and year-to-year comparisons are complicated by a number of factors, including special charges incurred throughout the first six months of 2001. Specifically, aggregate merger and restructuring charges total \$216 million and \$227 million before tax during the second quarter of 2001 and 2000, respectively. Of the second quarter 2001 charges, \$206 million (\$123 million after tax or \$0.09 per share) is recorded within merger and restructuring and \$10 million (\$6 million after tax or \$0.01 per share) is recorded in cost of products sold. Second quarter 2000 includes a \$111 million (\$81 million after tax or \$0.05 per share) charge reported as merger and restructuring, a \$32 million (\$20 million after tax or \$0.02 per share) charge recorded within cost of products sold, and \$84 million (\$83 million after tax or \$0.07 per share) recorded as adjustments to goodwill relating to the write-down of goodwill in the Monsanto restructuring.

Year-to-date 2001 aggregate merger and restructuring charges are \$362 million before tax, of which \$351 million (\$215 million after tax or \$0.17 per share) is reported as merger and restructuring and \$11 million (\$7 million after tax or \$0.01 per share) is recorded within cost of products sold. Year-to-date 2000 aggregate merger and restructuring charges amounted to \$688 million before tax. Of these charges, \$572 million (\$404 million after tax or \$0.30 per share) is recorded within merger and restructuring, \$32 million (\$20 million after tax or \$0.02 per share) is recorded within cost of products sold, and \$84 million (\$83 million after tax or \$0.07 per share) was recorded as adjustments to goodwill relating to the write-down of goodwill in the Monsanto restructuring.

Year-to-date 2001 includes charges of \$67 million (\$42 million after tax or \$0.03 per share) which was recorded in research and development (R&D) in association with the Sensus purchase acquisition and \$50 million (\$31 million after tax or \$0.02 per share) of expense in R&D related to an agreement with Celltech Group plc in connection with the compound CDP 870.

A charge of \$100 million (\$62 million after tax or \$0.05 per share) to selling, general and administrative (SG&A) relates to a charitable contribution and is

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

included in year-to-date 2000.

NET SALES

Consolidated net sales rose 5 percent to \$5.4 billion for the quarter and 6 percent to \$9.9 billion for the first six months as compared to the same periods of 2000. The increase in sales growth for both the quarter and first half of 2001 is the result of volume increases of 8 percent and 10 percent, respectively. These volume increases were driven primarily by sales of CELEBREX and ROUNDUP. For both periods, the volume increases were offset by a 3 percent negative impact of currency exchange rates coupled with a slight decrease in prices. The negative exchange impact is due to the strengthening U.S. dollar against most foreign currencies, particularly the euro and yen.

(Dollars in millions)	For the Three Months Ended June 30,			For the Six
	2001	Percent Change	2000	Months Ended June 30, 2001
Sales:				
Pharmaceuticals				
Prescription Pharmaceuticals	\$2,943	8%	\$2,732	\$5,672
Other Pharmaceuticals	470	5	448	951
Total Pharmaceuticals	3,413	7	3,180	6,623
Agricultural				
Agricultural Productivity	1,574	8	1,461	2,382
Seeds & Genomics	437	(20)	546	935
Total Agricultural	2,011	--	2,007	3,317
Total sales	\$5,424	5%	\$5,187	\$9,940

16

17

PHARMACEUTICAL NET SALES

Pharmaceutical net sales were \$3.4 billion for the second quarter and \$6.6 billion for the first six months of 2001, an increase over the same periods of 2000 of 7 percent and 10 percent, respectively. Excluding the impact of foreign currency exchange, global pharmaceutical sales increased 11 percent for the quarter and 14 percent year to date. Pharmaceutical sales growth was led by CELEBREX, which had improved sales of \$80 million, or 13 percent, for the quarter and \$204 million, or 18 percent, for the first half of 2001.

In the company's largest market, the U.S., pharmaceutical sales growth was 11 percent for both the quarter and six-month periods ended June 30, 2001. Japan, the company's second largest market, recorded a decline of 10 percent for the quarter and 9 percent for the first six months relative to the comparative periods of 2000. Excluding the negative impact of foreign currency exchange, Japan had sales growth of 4 percent and 3 percent for the quarter and first six months, respectively. Sales performance in the following table is based on location of the customer.

For the Three Months Ended

For the Six Months Ended

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

(Dollars in millions)	2001	June 30,		2000	2001	June 30,	
		Percent Change	%Chg. Excl. Ex.*			Percent Change	%Chg. Excl. Ex.*
United States	\$1,891	11%	11%	\$1,710	\$3,562	11%	11%
Japan	227	(10)	4	252	421	(9)	3
Italy	151	4	11	144	293	4	11
France	132	51	62	87	273	54	65
Germany	118	8	15	110	244	12	19
United Kingdom	103	(14)	(8)	121	222	--	8
Rest of world	791	5	13	756	1,608	9	17
Pharmaceutical net sales	\$3,413	7%	11%	\$3,180	\$6,623	10%	14%

* Underlying growth reflects the percentage change excluding currency exchange effects.

A comparison of the period-to-period consolidated net sales of the company's major pharmaceutical products (including generic equivalents where applicable) is provided in the table below.

(Dollars in millions)	For the Three Months Ended			For the Six Months Ended		
	2001	June 30, Percent Change	2000	2001	June 30, Percent Change	2000
CELEBREX	\$ 710	13%	\$ 630	\$1,359	18%	\$1,155
XALATAN	171	14	151	371	19	312
AMBIEN	112	(32)	165	327	23	265
CAMPTOSAR	180	62	111	317	66	191
DETROL LA/DETROL	158	70	93	293	52	194
GENOTROPIN	131	2	128	248	3	241
XANAX	91	13	81	167	2	165
MEDROL	87	13	78	159	11	144
CLEOCIN	74	(22)	95	149	(15)	175
DEPO-PROVERA	79	14	69	144	15	125
NICORETTE Line	63	16	54	129	18	109
PHARMORUBICIN/ELLECE	68	39	49	128	29	99
ARTHROTEC	77	7	73	122	(5)	128
FRAGMIN	58	3	56	111	(3)	114
ALDACTONE/Spiro Line	50	(2)	52	92	(4)	96
MIRAPEX	41	36	30	80	32	60
ROGAINE	30	(17)	36	64	(5)	68
CABASER/DOSTINEX	43	39	31	80	44	56
ZYVOX	30	59	19	53	175	19
PLETAL	20	29	15	46	87	24
Total	\$2,273	13%	\$2,016	\$4,439	19%	\$3,740

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

(Dollars in millions)	For the Three Months Ended June 30,			For the Six Mo
	2001	Percent Change	2000	2001
Net sales	\$2,943	8%	\$2,732	\$5,672
Cost of products sold	531	(2)	542	1,074
Research and development	485	(8)	526	1,055
Selling, general and administrative	1,182	2	1,157	2,316
EBIT*	719	51	476	1,156

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company. Merger and restructuring charges for pharmaceutical segments have been included as part of corporate costs in the determination of EBIT.

Prescription pharmaceutical net sales, which constituted more than 85 percent of total pharmaceutical sales during both the quarter and six-month period ending June 30, 2001, increased by 8 percent in the quarter and 11 percent year-to-date as compared to the respective periods of 2000. Sales growth in the prescription pharmaceutical business was driven by CELEBREX, XALATAN, CAMPTOSAR, DETROL LA and ZYVOX. Sales of these products for the quarter totaled \$1.3 billion, a 25 percent increase from the second quarter of 2000, and represented 43 percent of the quarter's prescription pharmaceutical sales compared to 37 percent for the year ago period. On a year-to-date basis, these products recorded sales of \$2.4 billion, a 28 percent increase from prior year, and represented 42 percent of the prescription pharmaceutical sales for the period.

CELEBREX, the company's leading product and the number-one selling prescription arthritis medication worldwide, recorded sales of \$710 million in the second quarter and \$1.4 billion in the first half of 2001. Global sales increased 13 percent in the quarter and 18 percent on a year-to-date basis driven by successful launches in Europe. Sales in the U.S. during the first six months of 2001 were negatively impacted by trade purchasing in the fourth quarter of 2000 due to a price increase.

XALATAN, the top-selling glaucoma medication in the U.S. and worldwide, achieved sales of \$171 million, a 14 percent increase over the second quarter of 2000. In the first six months of 2001, XALATAN recorded sales of \$371 million, a 19 percent increase. XALATAN is the number one prescribed glaucoma medication in the U.S., Europe and Japan. In the U.S., sales increased 11 percent to \$68 million for the quarter despite the introduction of two new competitors. During the quarter, the company received European Union approval for XALACOM, a fixed combination of XALATAN and timolol. European launches of XALACOM are expected to occur in the second half of 2001.

Sales of AMBIEN, the market leading treatment for short-term insomnia in the U.S., were \$112 million in the second quarter. Sales were negatively impacted by a previously announced increase in wholesale inventory levels during the first quarter preceding a March price increase. On a year-to-date basis, sales of AMBIEN increased 23 percent to \$327 million.

CAMPTOSAR, the leading treatment for colorectal cancer in the U.S., recorded

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

sales of \$180 million in the second quarter, an increase of 62 percent. Sales were positively influenced by an increase in trade purchasing during the quarter in connection with a price increase. First half sales reached \$317 million, a 66 percent increase. Since receiving U.S. Food and Drug Administration (FDA) approval in 2000 as a component of first-line treatment of metastatic

18

19

colorectal cancer, first-line use of CAMPTOSAR now accounts for more than half of CAMPTOSAR sales.

Sales of DETROL LA/DETROL, the world's leading treatment for overactive bladder, increased 70 percent to \$158 million in the second quarter and 52 percent to \$293 million in the first half. Sales in the U.S. were \$126 million reflecting strong demand for the new, once-daily DETROL LA which Pharmacia introduced in January. During the quarter, DETROL LA also received European Union approval. The company expects to launch the once-daily version across Europe in the second half of 2001 under various brand names including DETRUSITOL SR.

GENOTROPIN, the world's leading growth hormone, recorded sales of \$131 million during the second quarter, an increase of 2 percent. In the first six months, sales of GENOTROPIN were \$248 million. In the U.S., sales increased 19 percent in both the quarter and the year-to-date periods. Outside the U.S., sales gains were offset by weaker currencies in Europe and Japan.

ZYVOX, the company's new antibiotic for Gram-positive infections, recorded sales of \$30 million in the quarter, an increase of 59 percent. In the year-to-date period, ZYVOX sales reached \$53 million. ZYVOX is the first antibiotic from a completely new class of antibiotics in over 30 years. Following the approval and launch of ZYVOX in the United Kingdom in January, the European Union approved ZYVOX for marketing in Europe during the second quarter. The product will be sold under the brand name ZYVOXID when it is launched in Europe in the second half of 2001.

The company's older antibiotic product, CLEOCIN, declined 22 percent in the quarter and 15 percent in the first six months due to continued generic competition.

Sales of the company's Parkinson's disease drugs continued to grow at a rapid pace. MIRAPEX increased 36 percent in the second quarter to \$41 million. First half sales increased 32 percent to \$80 million. Meanwhile, sales of CABASER/DOSTINEX for Parkinson's disease and hyperprolactinemia grew 39 percent in the quarter and 44 percent in the first six months.

PHARMORUBICIN, a widely used chemotherapeutic agent for breast cancer, increased 39 percent to \$68 million in the quarter and 29 percent to \$128 million for the first half. Sales gains were driven by growing demand in the U.S., where the product was launched in the fourth quarter of 1999 under the trade name ELLENCE.

Sales of ARTHROTEC, one of the company's older arthritis medications, and XANAX, for anxiety, increased in the second quarter due to fluctuations in trade purchasing in advance of a price increase. Sales of these products in the first six months are more indicative of true demand. On a year-to-date basis, XANAX increased 2 percent and ARTHROTEC decreased 5 percent.

In the second quarter, sales of FRAGMIN, for the prevention of blood clots after surgery, increased 3 percent. Weaker currencies in Europe and Japan offset an 84 percent increase in U.S. sales of FRAGMIN.

In other developments related to the prescription pharmaceutical segment, Pharmacia received FDA approval to market AXERT for the treatment of migraine headaches. Pharmacia launched AXERT in the third quarter of 2001.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

The company announced the receipt of an approvable letter for SOMAVERT, the first in a new class of medicines called growth hormone receptor antagonists for the treatment of acromegaly. Pharmacia is working closely with FDA to resolve outstanding issues required for approval. Pharmacia also plans to provide additional data to the FDA in response to the not-approvable letter regarding parecoxib, a non-narcotic injectable analgesic.

19

20

Cost of products sold for the quarter and year-to-date periods ended June 30, 2001 and 2000 was \$531 million and \$542 million and \$1.1 billion and \$1.0 billion, respectively. A favorable shift in the product mix resulted in cost of products sold as a percent of sales to drop two percentage points to 18 percent in the quarter and one percentage point for the year-to-date period over the prior year.

Research and development (R&D) spending for the quarter decreased by \$41 million, or 8 percent, as compared to the second quarter of 2000. The decrease was due to lower development spending related to recent sNDA and NDA filings for the COX-2 projects (CELEBREX, valdecoxib, and parecoxib), ZYVOX and the cancellation of certain other projects. Spending for the year-to-date period ended June 30, 2001 increased 2 percent, or \$16 million, over the prior year. The increase was largely attributable to two events that occurred during the first quarter. During March, the company completed the acquisition of Sensus Drug Development Corporation and accounted for the transaction as a purchase. In conjunction with this accounting, an expense relating to in-process research and development was incurred for \$67 million. Also during the first quarter, the company entered into an agreement with Celltech Group plc for the co-development and co-promotion of Celltech's proprietary compound CDP 870. CDP 870 belongs to a new therapeutic class of medicines, which show promise in certain autoimmune and inflammatory diseases. In connection with the agreement, the company recorded an expense of \$50 million related to an up-front R&D payment. Offsetting these amounts were the aforementioned decreases in development spending and project cancellations, which have been realized throughout the first half of 2001.

Selling, general and administrative (SG&A) expenses increased between the quarterly and year-to-date periods ending June 30, 2001. An increase of \$25 million, or 2 percent, was realized for the quarter while the year-to-date period recorded an increase of \$211 million, or 10 percent, both compared to the corresponding prior-year periods. Mainly increased co-promotion payments, sales force expansion and promotional spending on strategic products drove the increases. The sales force expansion has been to support CELEBREX, LUNELLE, ACTIVELLA and ZYVOX.

OTHER PHARMACEUTICALS

(Dollars in millions)	For the Three Months Ended June 30,			For the Six
	2001	Percent Change	2000	2001
Net sales	\$ 470	5%	\$ 448	\$ 951
Cost of products sold	204	6	193	401
Research and development	43	3	42	86
Selling, general and administrative	136	(4)	141	280
EBIT*	100	5	95	204

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company. Merger and restructuring charges for pharmaceutical segments have been included as part of corporate costs in the determination of EBIT.

Net sales in the company's other pharmaceutical businesses are mainly comprised of consumer health care (over-the-counter products), animal health, pharmaceutical commercial services and diagnostics. Sales for the quarterly and year-to-date periods increased by \$22 million and \$26 million, respectively, in 2001 versus 2000. Increases in sales for the second quarter 2001 over 2000 was attributable to the pharmaceutical commercial services (PCS) business. Sales for this business increased 23 percent over the comparative quarter for 2000. In the year-to-date period, animal health, PCS and consumer health care were the drivers behind the favorable results with increases of 8 percent, 6 percent and 5 percent, respectively, versus the prior year.

20

21

AGRICULTURAL NET SALES

	For the Three Months Ended June 30,			For the Six Months Ended		
	2001	Percent Change	2000	2001	Percent Change	
	-----	-----	-----	-----	-----	-----
Agricultural Sales:						
Agricultural Productivity	\$ 1,574	8%	\$ 1,461	\$ 2,382	4%	\$
Seeds and Genomics	437	(20)	546	935	(10)	
Agricultural Sales	\$ 2,011	--	\$ 2,007	\$ 3,317	--	\$
=====						
Agricultural EBIT*:						
Agricultural Productivity	\$ 635	5%	\$ 605	\$ 774	(4)%	\$
Seeds and Genomics	15	n.m.	(94)	(17)	89	
Agricultural EBIT*	\$ 650	27%	\$ 511	\$ 757	18%	\$
=====						

n.m. = not meaningful

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company.

Net sales for the company's agricultural business were relatively unchanged for the three months and six months ended June 30, 2001 compared with the same periods of the prior year. For the three months ended June 30, 2001, sales of the ROUNDUP family of herbicides increased while the Seeds and Genomics segment

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

experienced higher soybean trait revenues which were more than offset by lower corn seed sales resulting from higher than anticipated corn seed returns in Latin America and fewer planted acres of corn in the United States. The strength of the U.S. dollar against foreign currencies, particularly the euro and the yen, negatively affected sales in the second quarter by 2 percent, or \$33 million.

Year-to-date, increased sales of the ROUNDUP lawn and garden products combined with increased biotechnology trait revenues and higher soybean seed sales were offset by lower conventional corn seed sales, resulting from higher than anticipated returns in Latin America and lower planted corn acreage in the U.S. and currency effects of a strong U.S. dollar. The strength of the U.S. dollar during the six months negatively affected sales by nearly 2 percent or \$60 million.

AGRICULTURAL PRODUCTIVITY SEGMENT

(Dollars in millions)	For the Three Months Ended June 30,			For the Six Months Ended	
	2001	Percent Change	2000	2001	Percent Change
Net Sales	\$ 1,574	8%	\$ 1,461	\$ 2,382	4%
EBIT*	635	5	605	774	(4)

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company.

21

22

Net sales for the Agricultural Productivity segment increased 8 percent in the second quarter of 2001 compared with the second quarter of 2000. Sales of the ROUNDUP family of herbicides and other glyphosate products (excluding ROUNDUP lawn and garden) rose 4 percent on higher volumes, primarily in the U.S. and Latin America, partly offset by a decline in sales in Asia, primarily attributable to lower prices, including the effects of currency. Higher sales in Latin America of branded ROUNDUP herbicide and other glyphosate products (excluding ROUNDUP lawn and garden) primarily reflected increased adoption of conservation tillage in Argentina. The Agricultural Productivity segment also benefited from a 16 percent increase in sales by other businesses, including ROUNDUP lawn and garden and POSILAC bovine somatotropin.

EBIT for the Agricultural Productivity segment rose 5 percent in the three months ended June 30, 2001 compared with the same period of 2000. Gross profit for the segment increased 2 percent on higher sales but gross profit as a percent of sales declined 3 percentage points. The decline in gross margin percentage was largely attributable to lower ROUNDUP prices, including the effects of branded product mix and the effects of currency fluctuations. Higher sales of ROUNDUP lawn and garden products, together with improved operational performance of the animal agriculture business, also contributed to the increase in EBIT. Operating expenses for the segment decreased 8 percent from the second quarter of 2000. SG&A and research spending as a percent of sales dropped 3 percentage points quarter over quarter, reflecting continued

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

cost management.

Year-to-date net sales for the Agricultural Productivity segment increased 4 percent over the same period in the prior year. Increased ROUNDUP lawn and garden product sales combined with higher sales in the animal agricultural business were partly offset by a decrease in net sales in certain selective chemistry products. Sales of ROUNDUP herbicide and other glyphosate products (excluding ROUNDUP lawn and garden) were nearly flat. Volumes of these products increased 12 percent but were offset by lower prices and product mix. In the United States, volumes increased 9 percent largely on increased demand for over-the-top applications used in conjunction with ROUNDUP READY seeds. Net sales in the U.S. were higher as modest price declines, driven largely by marketing programs and branded product mix, slightly offset volume increases. Sales of ROUNDUP herbicide also increased in Argentina where adoption of conservation tillage increased. However, sales in Canada, Australia, and Japan declined mainly from price competition, unfavorable weather conditions, and currency effects.

EBIT for the Agricultural Productivity segment decreased 4 percent, or \$29 million, in the first six months of 2001 compared with the same period of 2000. Excluding charges for restructuring in 2001, reduced SG&A and research and development spending offset lower gross profit for the segment. Gross profit of ROUNDUP and other glyphosate sales outside the U.S. were lower due to the strength of the U.S. dollar against other currencies combined with the mix of branded products sold.

SEEDS AND GENOMICS SEGMENT

(Dollars in millions)	For the Three Months Ended June 30,			For the Six Months Ended June 30,		
	2001	Percent Change	2000	2001	Percent Change	2000
Net Sales	\$ 437	(20)%	\$ 546	\$ 935	(10)%	\$ 1,035
EBIT*	15	n.m.	(94)	(17)	89	(10)

n.m. = not meaningful

* Earnings before interest and taxes (EBIT) is presented here to provide additional information about the company's operations. This item should be considered in addition to, but not as a substitute for or superior to, net earnings, cash flow or other measures of financial performance prepared in accordance with generally accepted accounting principles. Determination of EBIT may vary from company to company.

Net sales for the Seeds and Genomics segment decreased 20 percent to \$437 million in the second quarter of 2001 from \$546 million in the same quarter of 2000. The decline was mainly caused by higher than anticipated corn seed returns (approximately \$80 million) in Latin America during the second quarter. In addition, corn seed sales were lower in the United States as the result of lower corn planted acreage compared with the prior year. Trait revenues were relatively unchanged quarter to quarter reflecting higher soybean seed trait revenues offset by lower corn and cotton seed trait revenues.

EBIT for the Seeds and Genomics segment improved in the second quarter of 2001 to \$15 million compared with a loss of \$94 million in the same quarter of 2000.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

The second quarter of 2000 included an \$84 million write-off of goodwill and restructuring charges that exceeded those in 2001 by \$45 million. Excluding these one-time differences, earnings from the core business decreased nearly \$20 million. The reduction in operating expenses in 2001 was not sufficient to offset the lower segment gross profit resulting from lower conventional corn seed sales caused by higher than anticipated corn seed returns in Latin America and lower corn seed sales in the U.S.

For the six months ended June 30, 2001, net sales for the Seeds and Genomics segment fell 10 percent or \$99 million. Higher than anticipated corn seed returns in Latin America were primarily responsible for the decline. In the United States, increased revenues from biotechnology traits, mainly soybeans and cotton, and higher soybean sales volumes were offset by lower corn seed sales. Higher soybean trait revenue reflected the increased demand for ROUNDUP READY soybeans while cotton producers purchased more cotton seed stacked with BOLLGARD and ROUNDUP READY traits. The company estimates that seeds bearing its insect-resistant and ROUNDUP READY technologies were planted on approximately 80 million acres in the 2001 growing season, an increase of 11 percent over the previous growing season.

Year-to-date EBIT for the Seeds and Genomics segment improved from a loss of \$161 million in 2000 to a loss of \$17 million in 2001. The six month period for 2000 included the \$84 million write-off of goodwill and restructuring charges that exceeded the same six-month period of 2001 by \$35 million. Excluding these one-time differences, earnings improved \$25 million year-to-date. Lower gross profit from lower corn seed sales were more than offset by lower operating expenses and increased biotechnology trait revenues.

AGRICULTURAL OUTLOOK

Due to the seasonal nature of the agricultural business, Monsanto represents a disproportionately large amount of second-quarter sales and earnings. The first half of the year is largely focused on the peak agricultural season in the northern hemisphere. As the company enters the second half of the year, the southern hemisphere becomes increasingly important. As a result, second-half 2001 growth is somewhat dependent on the economic conditions in the key Latin American agricultural markets of Argentina and Brazil. Given the recent economic trends in those markets, the company will continue to closely track the conditions there. The company has taken several steps to help it manage these businesses for profitability. Importantly, the agricultural markets in Argentina and the soybean market in Brazil are export oriented with grain trading denominated largely in U.S. dollars. However, if the economic conditions, including currency exchange rates and conditions in the agricultural markets, deteriorate substantially, it could have a material adverse effect on the company's credit risk profile, financial position and profitability.

CORPORATE AND OTHER

Corporate expenses totaled \$305 million and \$162 million for the second quarters of 2001 and 2000, respectively. Merger costs included in these balances totaled \$138 million for 2001 and \$7 million in 2000. Additionally, restructuring charges associated with the pharmaceutical and corporate functions are included in the corporate expenses. These charges totaled \$37 million

23

24

and \$59 million for the second quarter of 2001 and 2000, respectively. Restructuring charges associated with the agricultural segments are included in the respective segments.

For the six-month periods ending June 30, 2001 and 2000, corporate expenses totaled \$571 million and \$814 million, respectively. Merger costs included in

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

these balances were \$194 million in 2001 and approximately \$470 million for 2000. Pharmaceutical and corporate restructuring charges included in corporate expense totaled \$105 million and \$59 million for the first half of 2001 and 2000, respectively. Year-to-date 2000 also included a \$100 million charitable contribution.

The net interest expense for the quarter decreased \$21 million, or 27 percent, in relation to the comparable quarter of 2000 and decreased \$46 million, or 31 percent, when comparing the six-month periods ending June 30, 2001 and 2000. The decreases are the result of significantly reduced net debt levels and increased cash balances.

The estimated annual effective tax rate for 2001 is 29 percent, excluding merger and restructuring and certain other costs. This compares with a 30-percent rate for the full year 2000.

MERGER AND RESTRUCTURING CHARGES

The company recorded an additional \$216 million of merger and restructuring charges during the second quarter of 2001 in connection with the merger and integration of the former Monsanto and Pharmacia & Upjohn companies into Pharmacia Corporation. These charges are part of the comprehensive integration plan approved by the board of directors during 2000. Of the total charges in the quarter, \$206 million, comprised of \$138 million of merger costs and \$68 million of restructuring expenses, was recorded on the merger and restructuring line of the consolidated statements of earnings and an additional \$10 million was recorded in cost of products sold.

For the six months ended June 30, 2001, the company recorded a total of \$362 million of merger and restructuring costs. Of this total, \$351 million, comprised of \$194 million of merger costs and \$157 million of restructuring expenses, was recorded on the merger and restructuring line of the consolidated statements of earnings and an additional \$11 million was recorded in cost of products sold.

The \$194 million of 2001 merger costs includes costs incurred to integrate the former companies into a single organization such as consultant and relocation costs. This effort includes the company's plan to exit its Sweden-based metabolic diseases research activities, biopharmaceutical development unit and the company's plasma business. As a result of this effort, the company entered into a definitive agreement on June 7, 2001, related to the partial divestiture of these operations, establishing Biovitrum AB (Biovitrum). The related estimated loss of \$50 million is included within the second quarter 2001 merger costs and included the write-down of the net assets to market value and certain transaction-related expenses. Under the Biovitrum-related agreements, Pharmacia will initially retain ownership of approximately 35 percent of the new company with the remaining shares owned by outside investors. It is possible that Pharmacia's share will be further reduced to below 20 percent as additional outside investors may participate in the new company by acquiring shares from Pharmacia. At the current 35 percent ownership level, the company will account for its share of Biovitrum using the equity method of accounting following the closing of the transaction. The closing occurred on July 31, 2001 and, accordingly, there were no cash flows associated with the transaction in the second quarter.

The \$78 million of aggregate restructuring costs for the quarter comprises \$28 million related to prescription pharmaceuticals, \$9 million associated with corporate and administrative functions and \$41 million in connection with the agricultural subsidiary. On a year-to-date basis, the company has recorded \$168 million of aggregate restructuring charges as follows: \$88 million associated with prescription pharmaceuticals, \$15 million associated with corporate and

25

administrative functions, \$2 million in connection with other pharmaceutical operations and \$63 million related to the agricultural subsidiary.

The \$28 million relating to prescription pharmaceuticals consists of \$17 million in connection with the involuntary termination of approximately 70 employees and \$11 million relating to asset impairments costs. For the six months ended June 30, 2001, the \$88 million total restructuring charges associated with prescription pharmaceuticals comprises \$63 million in connection with the involuntary separation of approximately 360 employees, \$17 million resulting from asset impairments and \$8 million associated with other exit costs.

The \$9 million associated with the corporate and administrative functions for the quarter includes \$4 million relating to the involuntary separation of approximately 30 employees and \$5 million resulting from asset impairments. The 2001 year-to-date total of \$15 million for corporate and administrative functions includes \$10 million relating to the involuntary separation of approximately 90 employees and the \$5 million of asset impairments. Although there are no charges associated with the other pharmaceutical operations during the second quarter 2001, the year-to-date restructuring balance includes \$2 million associated with the involuntary separation of approximately 10 employees.

The \$41 million of agricultural subsidiary restructuring charges for the quarter is composed of \$31 million on the merger and restructuring line and \$10 million on the cost of products sold line related to the write-off of inventories in connection with Monsanto's restructuring plan. The \$31 million in merger and restructuring comprises \$5 million relating to workforce reduction costs associated with the involuntary separation of approximately 110 employees, \$14 million relating to facility closures and other exit costs including contract terminations costs resulting from the exit of certain research programs and non-core activities, and \$12 million relating to the write-off of assets. For the 2001 year-to-date total of \$63 million (\$11 million in cost of products sold and \$52 million in merger and restructuring), Monsanto recorded \$20 million in connection with the involuntary separation of approximately 230 employees, \$18 million relating to facility closures and other exit costs, \$14 million in connection with the write-down of assets and \$11 million in cost of products sold in connection with the write-off of inventories.

During the second quarter 2000, the company recorded aggregate merger and restructuring charges of \$227 million. During that quarter, the company recorded on the merger and restructuring line an additional \$7 million of merger costs, totaling approximately \$470 million in merger-related costs for the first six months of 2000. These merger-related costs are comprised, in part, of transaction costs including investment bankers, attorneys, registration and regulatory fees and other professional services. In addition, these costs included various employee incentive and change-of-control costs directly associated with the merger. The latter includes a non-cash charge of \$232 million during the first quarter that was related to certain employee stock options that were repriced in conjunction with the merger pursuant to change of control provisions. Pursuant to the terms of these "premium options," at consummation of the merger, the original above-market exercise price was reduced to equal the fair market value on the date of grant.

The \$220 million of additional charges during the second quarter of 2000 represents restructuring charges and was recorded on several lines of the consolidated statements of earnings. \$104 million was recorded on the merger and restructuring line and included \$90 million associated with the involuntary separation of 424 employees and \$14 million relating to asset impairments and contract termination costs. An inventory write-off of \$32 million was recorded in cost of products sold and goodwill impairments of \$84 million were recorded

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

in the amortization and adjustment of goodwill line, both in connection with the restructuring of the agricultural subsidiary.

Of the second-quarter 2000 charges to merger and restructuring, \$59 million relates to the restructuring of corporate functions including the involuntary separation of 49 employees, primarily the result of duplicate positions. The remaining \$45 million of charges are associated with the

25

26

restructuring of agricultural products operations and include the involuntary separation of 375 employees throughout the world, mainly in research and development.

A rollforward from year-end 2000 of restructuring charges and spending associated with the current restructuring plans relating to the integration of the former Monsanto and Pharmacia & Upjohn companies and the restructuring of the agricultural products and other pharmaceutical operations is included in the table below. As of June 30, 2001, the company has paid a total of \$369 million relating to the separation of approximately 2,745 employees associated with these restructuring plans.

(Dollars in millions)	Workforce Reductions	Other Exit Costs	Total
December 31, 2000	\$ 192	\$ 15	\$ 207
Year-to-date charges	95	26	121
Year-to-date spending	(222)	(24)	(246)
June 30, 2001	\$ 65	\$ 17	\$ 82

Due to the comprehensive nature of the restructuring and integration, the company anticipates the restructuring activities to span multiple years with total merger and restructuring costs equaling \$2.0 billion to \$2.5 billion with annual savings in excess of \$600 million.

COMPREHENSIVE INCOME

Comprehensive income equals net earnings plus other comprehensive income (OCI). For Pharmacia Corporation, OCI includes currency translation adjustments, deferred amounts for hedging purposes, unrealized gains and losses on available-for-sale securities, and minimum pension liability adjustments. Comprehensive income for the three months ended June 30, 2001 and 2000, was \$708 million and \$319 million, respectively. For the six months ended June 30, 2001 and 2000, comprehensive income was \$727 million and \$423 million, respectively. The difference between net earnings and comprehensive income in both years was largely due to fluctuations in the currency translation adjustments reflecting the changes in the strength of the dollar against other currencies at June 30, 2001 as compared to the previous December 31, 2000.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

June 30,

December

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

(Dollars in millions)	2001	2000
Working capital	\$ 5,412	\$ 5,406
Current ratio	1.76:1	1.88:1
Debt to total capitalization	30.9%	29.3%

The company's working capital was mainly unchanged at June 30, 2001 as compared to year-end. Seasonal increases in accounts receivable relating to the agricultural business grew current assets while increases in short-term debt served to increase current liabilities. Seasonal commercial paper borrowing in the agricultural business and a reclassification of debt from long-term to short-term were mainly responsible for the mitigation of net working capital growth. The current ratio and debt-to-total-capitalization ratio were slightly unfavorable compared to December 31, 2000 due to the aforementioned seasonal activity.

26

27

During the second quarter, the company retired certain third party debt pertaining to the Employee Stock Ownership Plan (ESOP). The cash impact of the transaction was \$71 million.

During March 2001, the company acquired Sensus Drug Development Corporation. The cash paid in connection with this transaction was \$65 million.

On June 29, 2001, the company committed to a definitive agreement to retire \$700 million in debt securities. This action resulted in the reclassification of the debt from a long-term to a short-term classification in the condensed consolidated balance sheets during the period. The physical settlement of these securities occurred in July 2001.

The company continues to monitor the economic conditions in certain Latin American countries and the impact that an adverse change could have on working capital, liquidity and profitability. While the entire company has exposure to such an adverse event, the effects would be felt most strongly in the agricultural segments as indicated under "Agricultural Outlook" above.

The company's future cash provided by operations and borrowing capacity are expected to cover normal operating cash flow needs, planned capital acquisitions and dividend payments as approved by the board of directors for the foreseeable future.

CONTINGENT LIABILITIES AND LITIGATION

Various suits and claims arising in the ordinary course of business, including suits for personal injury alleged to have been caused by the use of the company's products, are pending against the company and its subsidiaries. The company also is involved in several administrative and judicial proceedings relating to environmental concerns, including actions brought by the U.S. Environmental Protection Agency (EPA) and state environmental agencies for remediation.

In April 1999, a jury verdict was returned against DEKALB Genetics (DEKALB) (which is now a wholly owned subsidiary of Monsanto) in a lawsuit filed in U.S. District Court in North Carolina. The lawsuit claims that a 1994 license agreement was induced by fraud stemming from nondisclosure of relevant information and that DEKALB did not have the right to license, make or sell products using the plaintiff's technology for glyphosate resistance under this

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

agreement. The jury awarded \$15 million in actual damages for unjust enrichment and \$50 million in punitive damages. DEKALB has appealed this verdict, believes it has meritorious grounds to overturn the verdict and intends to vigorously pursue all available means to have the verdict overturned. No provision has been made in the company's consolidated financial statements with respect to the award for punitive damages.

In June 1996, Mycogen Corporation, Mycogen Plant Sciences, Inc. and Agrigenetics filed suit against former Monsanto in California State Superior Court in San Diego alleging that the company failed to license, under an option agreement, technology relating to Bt corn and glyphosate-tolerant corn, cotton and canola. On October 20, 1997, the court construed the agreement as a license to receive genes rather than a license to receive germplasm. Jury trial of the damage claim for lost future profits from the alleged delay in performance ended March 20, 1998, with a verdict against the company awarding damages totaling \$175 million. On June 28, 2000, the California Court of Appeals for the Fourth Appellate District issued its opinion reversing the jury verdict and related judgment of the trial court, and directed that judgment should be entered in the company's favor. Mycogen's subsequent motion for rehearing has been denied. Mycogen's petition with the California Supreme Court requesting further review was granted on October 25, 2000, and their appeal of the reversal of judgment is continuing. No provision has been made in the company's consolidated financial statements with respect to this verdict.

27

28

Based on information currently available and the company's experience with lawsuits of the nature of those currently filed or anticipated to be filed which have resulted from business activities to date, the amounts accrued for product and environmental liabilities are considered adequate. While the results of litigation cannot be predicted with certainty, management's belief is that any potential remaining liability from such proceedings that might exceed amounts already accrued will not have a material adverse effect on the company's consolidated financial position, profitability or liquidity.

The company's estimate of the ultimate cost to be incurred in connection with environmental situations could change due to uncertainties at many sites with respect to potential clean-up remedies, the estimated cost of clean-up, and the company's share of a site's cost. With regard to the company's discontinued industrial chemical facility in North Haven, Connecticut, the company will be required to submit a corrective measures study report to the EPA. As the corrective action process progresses, it may become appropriate to reevaluate the existing reserves designated for remediation in light of changing circumstances. It is reasonably possible that a material increase in accrued liabilities will be required. It is not possible, however, to estimate a range of potential losses. Accordingly, it is not possible to determine what, if any, exposure exists at this time or when the expenditures might be made.

EXTRAORDINARY ITEMS

On June 28, 2001, the company retired certain debt obligations relating to one of the employee stock ownership plans. The principal amount of the debt was \$65 million. Certain costs related to the transaction, including a premium to retire the debt and other direct costs, were \$4 million (net of taxes of \$2 million) and have been classified as an extraordinary item on the company's consolidated statements of earnings.

Through a private transaction occurring on June 29, 2001, the company retired debt related to the adjustable conversion-rate equity securities (ACES) in the principal amount of \$700 million. Premium on the debt and other direct costs of \$8 million (net of taxes of \$5 million) were accrued as an extraordinary item. The physical settlement, including the exchange of cash, occurred in July 2001.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

NEW ACCOUNTING STANDARDS

On June 29, 2001, the Financial Accounting Standards Board approved for issuance Statement of Financial Accounting Standards (SFAS) No. 141 "Business Combinations". The new rules require that the purchase method of accounting be used for all business combinations after June 30, 2001. The use of the pooling of interests method is now prohibited. There was no impact on the company's financial statements with the adoption of these rules.

Also during the quarter, the Financial Accounting Standards Board approved for issuance SFAS No. 142 "Goodwill and Other Intangible Assets". These new rules change the accounting methodology for goodwill from a model which amortizes goodwill to one which evaluates it for impairment. Amortization of goodwill, including previously recorded goodwill, will end upon adoption of the new rules. The new rules also eliminate amortization of certain other intangibles - those with indefinite useful lives. These, too, will be subject to the impairment test. The company is currently evaluating the effects the new rules may have on its financial statements and will adopt SFAS 142 as of January 1, 2002.

On January 1, 2001, the company adopted SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities". This statement requires companies to record derivatives on the balance

28

29

sheet as assets and liabilities measured at fair value. The accounting treatment of gains and losses resulting from changes in the value of derivatives depends on the use of the derivative and whether it qualifies for hedge accounting. Gains and losses of non-hedging instruments attributable to changes in the fair value are recorded in earnings. If elected and qualified, special hedge accounting is available whereby gains and losses of derivatives and certain other instruments can be offset or deferred.

Under the new rules, the net consolidated statements of earnings effect of adopting SFAS 133 is presented as a cumulative effect adjustment of an accounting change and is less than \$1 million (net of tax). This amount is comprised of the excluded component of instruments previously designated in cash flow hedges and other changes in the recorded basis to bring derivatives to fair value, both of which were less than \$1 million on an individual basis. There was no net impact to the cumulative effect adjustment required to reflect the fair value of derivatives that are designated as fair value hedges, as the adjustments to recognize the difference between the carrying values and the fair values of hedged items and related derivatives offset. A similar cumulative effect adjustment in the amount of \$3 million (net of tax) has been made on the condensed consolidated balance sheets to other comprehensive income. This amount reflects the deferred amount of derivative instruments previously designated in cash flow hedges. Upon adopting SFAS 133, the company elected, in accordance with the rules, to reclassify \$52 million of held-to-maturity securities as available-for-sale securities. The unrealized gain associated with this reclassification is not material and is recorded in shareholders' equity.

EURO CONVERSION

Effective January 1, 1999, eleven European countries began operating with a new common currency, the euro. This has now increased to twelve with the addition of Greece. The euro will completely replace these countries' national currencies by January 1, 2002.

The conversion to the euro requires changes in the company's operations as systems and commercial arrangements are modified to deal with the new currency.

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

Management created a project team to evaluate the impact of the euro conversion on the company's operations and develop and execute action plans, as necessary, to successfully effect the change. As of December 31, 2000, the company's systems were euro compliant, and during 2001 they all will have been converted to the euro as their local currency. The cost of this effort through 2000 was approximately \$9 million with an additional amount of \$3 million expected before January 1, 2002. The conversion to the euro may have competitive implications on pricing and marketing strategies. However, any such impact is not known at this time. At this point in its overall assessment, management believes the impact of the euro conversion on the company will not be significant. Still, uncertainty exists as to the effects the euro currency will have on the marketplace and, as a result, there is no guarantee that all problems will be foreseen and corrected, or that no material disruption of the company's business will occur.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At June 29, 2001, the company entered into a definitive agreement for the retirement of \$700 million in fixed-rate debt securities. The effect of this retirement served to reduce the company's exposure to interest rate risk. Physical settlement of these securities occurred during July 2001.

There are no other material changes related to market risk from the disclosures in Pharmacia Corporation's Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2000.

29

30

PART II - OTHER INFORMATION

ITEM 5. OTHER INFORMATION

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this Report, as well as in other documents incorporating by reference all or part of this Report, are "forward-looking statements" provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. These statements are made to enable a better understanding of the Company's business, but because these forward-looking statements are subject to many risks, uncertainties, future developments and changes over time, actual results may differ materially from those expressed or implied by such forward-looking statements. Examples of forward-looking statements are statements about anticipated financial or operating results, financial projections, business prospects, future product performance, future research and development results, anticipated regulatory filings and approvals, and other future matters.

These forward-looking statements are based on the information that was currently available to the Company, and the expectations and assumptions that were deemed reasonable by the Company, at the time when the statements were made. The Company does not undertake any obligation to update any forward-looking statements in this Report or in any other communications of the Company, whether as a result of new information, future events, changed assumptions or otherwise, and all such forward-looking statements should be read as of the time when the statements were made, and with the recognition that these forward-looking statements may later prove to be incorrect.

Among the many factors that may cause or contribute to actual results or events being materially different from those expressed or implied by such forward-looking statements are acquisitions, divestitures, mergers, restructurings or strategic initiatives that change the Company's structure or

Edgar Filing: PHARMACIA CORP /DE/ - Form 10-Q

business; competitive effects from current and new products, including generic products, sold by other companies; price constraints imposed by managed care groups, institutions and government agencies; governmental actions which result in lower prices for the Company's products; the Company's ability to discover and license new compounds, develop product candidates, obtain regulatory approvals and market new products; the Company's ability to secure and defend its intellectual property rights; the Company's ability to attract and retain management and other key employees; product developments, including adverse reactions or regulatory actions; social, legal, political and governmental developments, especially those relating to health care reform, pharmaceutical pricing and agricultural biotechnology; seasonal and weather conditions affecting agricultural markets; new product, antitrust, intellectual property or environmental liabilities; changes in foreign currency exchange rates or in general economic or business conditions; changes in applicable laws and regulations; changes in accounting standards or practices; and such other factors that may be described elsewhere in this Report or in other Company filings with the U.S. Securities and Exchange Commission ("SEC").

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits - See the Exhibit Index

(b) Reports on Form 8-K during the quarter ended June 30, 2001:

Report on Form 8-K dated June 22, 2001 was filed pursuant to Item 5 (Other Events) and Item 7 (Financial Statements and Exhibits).

30

31

SIGNATURE:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHARMACIA CORPORATION
(Registrant)

DATE: August 13, 2001

/S/R. G. Thompson
R. G. Thompson
Senior Vice President
and Corporate Controller

31

32

EXHIBIT INDEX

These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.

Exhibit Number	Description
-------------------	-------------

-
-
- 2. Omitted - Inapplicable
 - 4. Omitted - Inapplicable
 - 10. Omitted - Inapplicable
 - 11. Omitted - Inapplicable; see Note G of Notes to Financial Statements on page 9.
 - 15. Omitted - Inapplicable
 - 18. Omitted - Inapplicable
 - 19. Omitted - Inapplicable
 - 22. Omitted - Inapplicable
 - 23. Omitted - Inapplicable
 - 24. Omitted - Inapplicable
 - 99. Omitted - Inapplicable